Everest Medicines (HKG: 1952) announced that the Taiwan Food and Drug Administration (TFDA) has approved the New Drug Application for Velsipity film‑coated tablets (etrasimod) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, loss of response, or intolerance to conventional therapy or a biological agent. The approval marks that etrasimod has now been approved for marketing across all authorized territories of Everest Medicines.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | TFDA (Taiwan region) |
| Approval Type | New Drug Application (marketing authorization) |
| Product | Velsipity film‑coated tablets (etrasimod) |
| Indication | Moderately to severely active ulcerative colitis in adults with inadequate response, loss of response, or intolerance to conventional therapy or a biologic |
| Approval Date | 23 Oct 2026 |
| Milestone | Full coverage of all Everest Medicines authorized territories |
| Related Filing | NMPA accepted marketing authorization transfer application for Velsipity manufacturing localization (overseas → domestic), granted Priority Review (Sept 2026) |
Drug Profile & Mechanism of Action
- Molecule: Etrasimod – an once‑daily oral, highly selective sphingosine‑1‑phosphate (S1P) receptor modulator.
- Target: Designed with optimized pharmacology to bind selectively to S1P receptors 1, 4 and 5, modulating lymphocyte trafficking implicated in UC pathogenesis.
- Administration: Oral, once‑daily dosing – offering a pill‑based alternative to infused or injected biologics for patients who have failed prior therapies.
- Origin: Originally developed by Arena Pharmaceuticals; Everest Medicines acquired exclusive rights to develop, manufacture and commercialize etrasimod in Greater China and South Korea from Arena in 2017. Arena was subsequently acquired by Pfizer in 2022.
- Global Footprint: Marketing authorizations to date span the United States, European Union, Canada, Japan, Australia, United Kingdom, Switzerland, Israel, Turkey, India, as well as Macao SAR, Singapore, Hong Kong SAR, mainland China, South Korea and the Taiwan region.
Disease Landscape & Competitive Position
- Unmet Need: Ulcerative colitis is a chronic, relapsing inflammatory bowel disease; a substantial share of patients lose response to or cannot tolerate conventional therapies and first‑line biologics, creating persistent demand for new mechanisms with oral convenience.
- Class Differentiation: S1P receptor modulators represent a distinct oral mechanism versus anti‑TNF biologics, JAK inhibitors and integrin antagonists, potentially expanding the post‑biologic treatment armamentarium.
- Regulatory Completeness: With TFDA approval, Everest Medicines has achieved full regulatory coverage of its licensed territories, enabling synchronized commercialization across Greater China and South Korea.
Market Impact & Outlook
- Territory Completion: The TFDA approval removes the last regulatory gap in Everest Medicines’ licensed footprint, allowing full‑scale commercial execution of Velsipity across all authorized markets.
- Manufacturing Localization: The NMPA’s Priority Review of the marketing authorization transfer application (accepted September 2026) signals an accelerated path toward domestic production of Velsipity in mainland China, potentially improving supply resilience and cost structure.
- Portfolio Strength: Etrasimod joins Everest Medicines’ commercial portfolio as a fully approved asset across 16+ jurisdictions worldwide, reinforcing the company’s position as a specialty‑pharma licensee bridging global innovation to Asian markets.
- Next Milestones: NMPA decision on the manufacturing localization transfer; commercial rollout progress in the newly approved Taiwan market. Timing not disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding regulatory outcomes, manufacturing localization timelines, and commercial expectations for Velsipity (etrasimod). Actual results may differ materially due to risks including regulatory review timelines, supply‑chain transition, market adoption, and competitive dynamics.-Fineline Info & Tech
